Back

prof. dr. S.C. Linn

prof. dr. S.C. Linn

Full Professor
prof. dr. S.C. Linn
  • Department of Pathology

Research Programs

Strategic Program Cancer

Biography

Biography

Dr. Sabine Linn is a professor of translational oncology focusing on breast cancer at Utrecht University, The Netherlands. Linn received her medical degree (1991, cum laude) at the State University Leiden, The Netherlands, and her internal medicine board certification (2000) at the University Medical Center Utrecht, The Netherlands. She earned her PhD (1998) on the subject of multidrug resistance in solid tumors from the Free University of Amsterdam under supervision of prof. Dr H.M. Pinedo.
She was awarded a Dutch Cancer Society Research Fellowship in 2000 and developed two conditional knock-out mouse models, one for non-small cell lung cancer and one for small cell lung cancer, respectively, in close collaboration with Dr Ralph Meuwissen in the laboratory of prof. Dr A.J. Berns at the Netherlands Cancer Institute, Amsterdam, The Netherlands. From 2001 to 2002 she was a postdoctoral research fellow in the laboratories of prof. Dr P.O. Brown, and prof. Dr M. van de Rijn, at Stanford University Medical School, Stanford, CA, where she contributed to the development of a molecular classification for soft tissue sarcomas. She returned to the Netherlands Cancer Institute in Amsterdam, where she earned her medical oncology certification (2002-2005) and became a senior staff member of the Division of Medical Oncology (2003).
Since 2005 she has also been a group leader at the Division of Molecular Pathology at the Netherlands Cancer Institute where she and her research group focus on the molecular dissection of breast cancer by differential drug sensitivity. To further develop this research line Dr. Linn was awarded a Dutch Cancer Society Clinical Research Award in 2006. From 2008-2012, Dr Linn served as chair of the Working Group on (neo)adjuvant systemic therapy of the Dutch Breast Cancer Trialists' Group (BOOG).

 

Side Activities

Neven activiteiten van Sabine Linn

 

 

Family Name:                   

Linn

Christian names:             

Sabine Charlotte

BIG number:                     

99032942301

Working address:             

Dept. of Medical Oncology

Netherlands Cancer Institute

Plesmanlaan 121

1066 CX  Amsterdam

The Netherlands

Telephone:                       

+31 20 5129111

Fax:                                   

+31 20 5122572                                               

 

 

 

 

Advisory boards and consultancies

 

2012 – present                

Function: Member Scientific Advisory Board

Organization: Cergentis, a spin-off company for targeted amplification of complete genes, The Netherlands

Personal income: No

 

2016                                      

Function: Member Lynparza (Olaparib) AstraZeneca Global Advisory Board

Organization: AstraZeneca

Personal income: No

 

2016 – 2017                     

Function: Member IBM Watson Health Oncology Global Advisory Board

Organization: IBM, Boston, MA, USA

Personal income: No

                                               

 

Educational and scientific committees

 

2003 – 2020                       

Function: Member of the NKI-AVL Organizing Committee for Continuing Medical Education Program for Dutch Medical Oncologists “DONAMO (DOorlopende NAscholing Medische Oncologie)”

Organization: Netherlands Cancer Institute, Amsterdam, Netherlands

Personal income: No

 

2007 – 2015                       

Function: Member of the Dutch Society for Medical Oncology (NVMO) Advisory Board for the Dutch Institute for Healthcare Improvement (CBO) Breast Cancer Guidelines

Organization: Dutch Institute for Healthcare Improvement (CBO)

Personal income: No

 

2008 – 2013                       

Function: Chair Working Group (neo)adjuvant systemic therapy of Borstkanker Onderzoek Groep (BOOG) (Dutch Breast Cancer Trialists’ Group)

Organization: Dutch Breast Cancer Trialists’ Group

Personal income: No

 

2013 – 2019                      

Function: Member of Program Committee of Dutch and Flemish Annual Oncology Days (NVMO Oncologiedagen Nederland en Vlaanderen)

Organization: NVMO (Nederlandse Vereniging voor Medische Oncologie)

Personal income: No

 

2014 – present                

Function: Member Committee on Personalised Medicine

Organization: ZonMw, The Netherlands

Personal income: No

 

2015 - present                 

Member Editorial Board of Breast Cancer Research

Organization: Springer Nature

Personal income: No

 

2015                                      

Function: Member Scientific Advisory Group

Organization: European Medicines Agency (EMA) London, UK

Personal income: No

 

2016 – 2017                      

Function: Member RiskAp Expert Group on breast cancer screening

Organization: German Federal Ministry of Education and Research

Personal income: No

 

2016 – 2017                    

Function: Member Scientific Evaluation Committee Institut National du Cancer, France

Organization: Institut National du Cancer (INCA), Paris, France

Personal income: No

 

2016 – 2017                       

Function: Member Expert Review Panel CRUK and EPSRC Cancer Imaging Centres (Oxford University, Cambridge University, King’s College London/University College London, The Institute of Cancer Research)

Organization: Cancer Research United Kingdom (CRUK)

Personal income: No

 

2016 – 2017                       

Function: Member IMPAKT 2017 Scientific Committee, Brussels, Belgium

Organization: ESMO (European Society of Medical Oncology) and BIG (Breast International Group)

Personal income: No

 

2016 – 2018                       

Function: Member ESMO 2018 scientific subcommittee breast cancer, early

Organization: ESMO (European Society of Medical Oncology)

Personal income: No

 

2017 – 2019                       

Function: Co-chair (with Alberto Bardelli) ESMO-EACR 2019 scientific subcommittee Translational Research

Organization: ESMO (European Society of Medical Oncology)

Personal income: No

 

2017 – 2020                       

Function: Member evaluation board of the panel LS4 “Physiology, Pathophysiology and Endocrinology” for European Research Council  Consolidator Grants (CoG) in 2018, and 2020

Organization: European Commission

Personal income: Yes, > 2,200 Euro/year

 

2021 – present                

Function: Member VIDI committee Dutch Research Council (NWO)

Organisation: Dutch Research Council (NWO)

Personal income: yes, < 2,200 euro/year

 

Research Output (113)

Prognosis of pregnancy-associated breast cancer:inferior outcome in patients diagnosed during second and third gestational trimesters and lactation

Suelmann B. B.M., Bakhuis C. F.J., van Dooijeweert C., Verloop J., Zweemer R., Linn S., van der Wall E., van Diest P. J. 2022, In: Breast Cancer Research and Treatment. 192 , p. 175-189 15 p.

Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)

van Rossum Annelot G J, Mandjes Ingrid A M, van Werkhoven Erik, van Tinteren Harm, van Leeuwen-Stok A Elise, Nederlof Petra, Portielje Johanna E A, van Alphen Robbert J, Platte Els, van den Broek Daan, Huitema Alwin, Kok Marleen, Linn Sabine C, Oosterkamp Hendrika M 1 Dec 2021, In: Breast care (Basel, Switzerland). 16 , p. 598-606 9 p.

Receptor status of breast cancer diagnosed during pregnancy: A literature review

Bakhuis Carsten F. J., Suelmann Britt B. M., van Dooijeweert Carmen, Linn Sabine, van der Wall Elsken, van Diest Paul J. Dec 2021, In: Critical Reviews in Oncology Hematology. 168

The tale of TILs in breast cancer:A report from The International Immuno-Oncology Biomarker Working Group

El Bairi Khalid, Haynes Harry R., Blackley Elizabeth, Fineberg Susan, Shear Jeffrey, Turner Sophia, de Freitas Juliana Ribeiro, Sur Daniel, Amendola Luis Claudio, Gharib Masoumeh, Kallala Amine, Arun Indu, Azmoudeh-Ardalan Farid, Fujimoto Luciana, Sua Luz F., Liu Shi Wei, Lien Huang Chun, Kirtani Pawan, Balancin Marcelo, El Attar Hicham, Guleria Prerna, Yang Wenxian, Shash Emad, Chen I. Chun, Bautista Veronica, Do Prado Moura Jose Fernando, Rapoport Bernardo L., Castaneda Carlos, Spengler Eunice, Acosta-Haab Gabriela, Frahm Isabel, Sanchez Joselyn, Castillo Miluska, Bouchmaa Najat, Md Zin Reena R., Shui Ruohong, Onyuma Timothy, Yang Wentao, Husain Zaheed, Willard-Gallo Karen, Coosemans An, Perez Edith A., Provenzano Elena, Ericsson Paula Gonzalez, Richardet Eduardo, Mehrotra Ravi, Sarancone Sandra, Ehinger Anna, Linn Sabine, Van Diest Paul J., Dec 2021, In: npj Breast Cancer. 7

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients

Dackus Gwen M H E, Jóźwiak Katarzyna, Sonke Gabe S, van der Wall Elsken, van Diest Paul J, Siesling Sabine, Hauptmann Michael, Linn Sabine C 2 Nov 2021, In: Journal of the National Cancer Institute. 113 , p. 1506-1514 9 p.

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women

Joosten Stacey E.P., Wellenstein Marius, Koornstra Rutger, van Rossum Annelot, Sanders Joyce, van der Noort Vincent, Ferrandez Maria C., Harkes Rolf, Mandjes Ingrid A.M., Rosing Hilde, Huitema Alwin, Beijnen Jos H., Wesseling Jelle, van Diest Paul J., Horlings Hugo M., Linn Sabine C., Zwart Wilbert 20 Oct 2021, In: npj Breast Cancer. 7 , p. 1-8

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer

Ragusi Max Aa, Winter-Warnars Gonneke Ao, Wesseling Jelle, Linn Sabine C., Beets-Tan Regina G., van der Velden Bas Hm, Elias Sjoerd G., Gilhuijs Kenneth Ga, Loo Claudette E. 1 Jul 2021, In: The British journal of radiology. 94 , p. 1-10 10 p.

A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer

Geenen Jill J J, Dackus Gwen M H E, Schouten Philip C, Pluim Dick, Marchetti Serena, Sonke Gabe S, Jóźwiak Katarzyna, Huitema Alwin D R, Beijnen Jos H, Schellens Jan H M, Linn Sabine C 15 Jun 2021, In: International Journal of Cancer. 148 , p. 3041-3050 10 p.

Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017

van der Meer Daniël J., Kramer Iris, van Maaren Marissa C., van Diest Paul J., C. Linn Sabine, Maduro John H., J.A. Strobbe Luc, Siesling Sabine, Schmidt Marjanka K., Voogd Adri C. 1 May 2021, In: International Journal of Cancer. 148 , p. 2289-2303 15 p.

BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumour BRCA1 mutation

Wang Y., Rosenberg E. H., Dackus G. M. H. E., Broeks A., Cornelissen S., van Diest P. J., Hauptmann M., Ter Hoeve N., De Jong V., Jozwiak K., Koop E., Nederlof P. M., Opdam M., Siesling S., Stathonikos N., Voogd A., Vreuls W., Kok M., Linn S. C., Schmidt M. K. May 2021, In: Annals of Oncology. 32 , p. S24-S25

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet